Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of JMT103 in postmenopausal osteoporosis
CTR20212746Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of narlumosbart in postmenopausal osteoporosis (5 arms), sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoint: Percent change from baseline in lumbar spine bone mineral density at month 12. Started Apr 2022; status: active.
02
Drugs
narlumosbart
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on CTR20212746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212746.